ERAS trades higher as a shareholder investigation spotlights ERAS-0015 disclosure and comparison risks
Market Chameleon (Mon, 26-Oct 11:38 AM)
Erasca draws shareholder scrutiny after ERAS-0015 comparisons and IP risk allegations
Market Chameleon (Tue, 20-Oct 11:15 AM)
Erasca Receives FDA Fast Track for ERAS-0015 in Pancreatic Cancer: Phase 1 Data Shows 57% Response Rate
Market Chameleon (Mon, 24-Aug 8:51 AM)
